Stomach Cancer Treatment Market Scope & Overview:

To Get More Information on Stomach Cancer Treatment Market - Request Sample Report

The Stomach Cancer Treatment Market Size was valued at USD 4.84 billion in 2023, and is expected to reach USD 15.04 billion by 2032, and grow at a CAGR of 13.45% over the forecast period 2024-2032.

The fifth most frequent kind of cancer worldwide and one of the main causes of cancer-related fatalities is gastric cancer. In 2020, over 1.1 million new instances of the disease were reported globally, according to Globocan. During the projection period, it is projected that the rising disease burden and the approval of pipeline candidates will drive the market's expansion. Risk factors for stomach cancer include alterations in lifestyle, such as smoking and drunkenness, an increase in obesity, and a rise in gastroesophageal reflux syndrome. Asia Pacific and Europe have the highest disease incidence rates, respectively.

In industrialised nations like the U.S., targeted medications like Herceptin and Cyramza are routinely used to treat gastric cancer, whereas chemotherapy is still the go-to treatment in developing nations like China and India. Few medications have been licenced for treating the disease's severe metastatic stages. The treatment of advanced metastatic stages of the illness is anticipated to change with the introduction of PD-1 inhibitors like Opdivo and Keytruda. The approval of novel immunotherapy and targeted medications is predicted to boost market expansion during the course of the forecast.

Stomach Cancer Treatment Market Dynamics

DRIVERS

• Advances in Treatment Modalities and an Increasing Incidence of Stomach Cancer

• The use of minimally invasive procedures is expanding due to government initiatives and funding.

One important market driver is the increased incidence of stomach cancer around the world. The aging of the population, dietary habits, and lifestyle changes all play a role in the rising prevalence of stomach cancer. Treatment outcomes for patients with stomach cancer have improved as a result of the introduction of novel and targeted medicines, such as immunotherapies, precision medicine, and combination therapy. These developments encourage market expansion since they provide improved efficacy and fewer adverse effects. The development of the market is significantly influenced by government programs that raise cancer awareness, early detection programs, and financing for research and development of treatments for stomach cancer.

RESTRAIN

• Limited Early Detection and Awareness and High Treatment Costs.

• Negative Treatment Effects.

OPPORTUNITY

• Emerging Markets, Personalised Medicine.

Opportunities for more precise and successful stomach cancer therapies are presented by the growing emphasis on personalized medicine, which is based on patients' genetic profiles and tumour features. Untapped markets in developing nations offer big chances for market participants to grow their presence and offer affordable treatment alternatives to more people.

CHALLENGES

• Barriers to regulation and drug resistance.

IMPACT OF RUSSIAN-UKRAINE WAR

Armed conflicts and wars have the potential to seriously damage the infrastructure supporting the healthcare industry, including hospitals, clinics, and research institutions. For patients in the impacted areas, this disruption might make it more difficult to find and receive treatment options for stomach cancer. Supply-Chain Breakdowns The battle may interfere with the flow of drugs, medical supplies, and other vital materials required for treating stomach cancer. This can affect patient care by causing shortages and higher prices for these products. Limited Access to Medical Expertise Ongoing wars may force healthcare workers to relocate, leaving afflicted communities with little access to specialized medical knowledge for the treatment of stomach cancer. Redirection of Funding Governments may divert cash and resources from healthcare to defence and security during times of war, thus lowering investments in the healthcare sector, including cancer therapy.

IMPACT OF ONGOING RECESSION

Lower Healthcare Costs Individuals and families may experience financial difficulties during a recession, which could result in lower healthcare spending overall. To conserve money, patients may decide to put off or skip non-urgent medical procedures, such as stomach cancer screenings and treatments. Delays in Diagnosis Economic uncertainty and financial constraints may cause stomach cancer diagnoses to be delayed because patients may be reluctant to seek immediate medical assistance. When cancer is discovered later on due to a delayed diagnosis, it may already be in a more advanced stage, which could alter how well it responds to therapy. Effect on Healthcare Professionals During a recession, healthcare providers, including hospitals and clinics, may face financial difficulties. Healthcare facilities may be under pressure, which could impair their capacity to deliver high-quality care. These pressures include decreased patient volumes, postponed payments, and rising prices for medical supplies and equipment. belly cancer Treatment for stomach cancer can be expensive, particularly with the development of cutting-edge medicines and specialised medications. Patients may have trouble affording these pricey treatments during a recession, which could reduce their treatment options and reduce their effectiveness. Clinical research and trials: The financing for clinical trials and research into stomach cancer may be impacted by budget cuts brought on by the recession. New therapeutic choices and cutting-edge remedies may not be available as soon as planned due to slower research and development progress.

Stomach Cancer Treatment Market Segmentation

By Treatment Type

• Immunotherapy

• Targeted Therapy

• Chemotherapy

• Radiation Therapy and Surgery

By Disease Indication

• Gastric Cancer/Gastroesophageal Junction Cancer

• Gastrointestinal Stromal Tumors

• Route of Administration

• Oral

• Injectable

By Drug Class

• PD-1/PD-L1 Inhibitors

• HER2 Antagonists

• VEGFR2 Antagonists

• Others

By Distribution Channel

• Hospital Pharmacies

• Specialty & Retail Pharmacies

• Others

REGIONAL COVERAGE

North America

• US

• Canada

• Mexico

Europe

• Eastern Europe

  • Poland

  • Romania

  • Hungary

  • Turkey

  • Rest of Eastern Europe

• Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Netherlands

  • Switzerland

  • Austria

  • Rest of Western Europe

Asia Pacific

• China

• India

• Japan

• South Korea

• Vietnam

• Singapore

• Australia

• Rest of Asia Pacific

Middle East & Africa

• Middle East

  • UAE

  • Egypt

  • Saudi Arabia

  • Qatar

  • Rest of Middle East

• Africa

  • Nigeria

  • South Africa

  • Rest of Africa

Latin America

• Brazil

• Argentina

• Colombia

• Rest of Latin America

Stomach Cancer Treatment Market Regional Analysis

With a revenue share of more than 55.04%, Asia Pacific commanded the gastric cancer therapy market in 2023. This is mostly brought on by the greater incidence of stomach cancer in this area. Around 139,000 new cases were reported in Japan in 2020, whereas 480,000 were reported in China. Chemotherapy is the most popular treatment choice in nations like China, but the presence of a robust product pipeline and the anticipated approval of the treatments will support regional growth throughout the forecast period.

Due to rising investments in the creation of cutting-edge treatment alternatives and an increasing target patient population, Europe is anticipated to experience significant growth over the course of the projected period.

Do You Need any Customization Research on Stomach Cancer Treatment Market - Enquire Now

Key Players

The major players are Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd, Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis, Bristol Myers Squibb Company, and others.

RECENT DEVELOPMENTS

Bold Therapeutics: In May 2021, For its bold-100, a ruthenium-based small molecule therapy that is a first in class, Bold Therapeutics was awarded the orphan Drug Designation (ODD).

Bristol Myers Squibb: In April 2021,The first immunotherapy for the first-line treatment of gastric cancer, opdivo (nivolumab), was approved by the US FDA for Bristol Myers Squibb.